AU2002218461A1 - Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis - Google Patents

Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Info

Publication number
AU2002218461A1
AU2002218461A1 AU2002218461A AU2002218461A AU2002218461A1 AU 2002218461 A1 AU2002218461 A1 AU 2002218461A1 AU 2002218461 A AU2002218461 A AU 2002218461A AU 2002218461 A AU2002218461 A AU 2002218461A AU 2002218461 A1 AU2002218461 A1 AU 2002218461A1
Authority
AU
Australia
Prior art keywords
atherosclerosis
prevention
treatment
compositions containing
methods employing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002218461A
Other versions
AU2002218461B2 (en
Inventor
Jacob George
Gideon Halperin
Dror Harats
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Priority claimed from PCT/IL2001/001080 external-priority patent/WO2002041827A2/en
Publication of AU2002218461A1 publication Critical patent/AU2002218461A1/en
Application granted granted Critical
Publication of AU2002218461B2 publication Critical patent/AU2002218461B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002218461A 2000-11-24 2001-11-22 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis Ceased AU2002218461B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25257400P 2000-11-24 2000-11-24
US60/252,574 2000-11-24
PCT/IL2001/001080 WO2002041827A2 (en) 2000-11-24 2001-11-22 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
AU2002218461A1 true AU2002218461A1 (en) 2002-08-08
AU2002218461B2 AU2002218461B2 (en) 2006-09-07

Family

ID=22956589

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1846102A Pending AU1846102A (en) 2000-11-24 2001-11-22 Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis
AU2002218461A Ceased AU2002218461B2 (en) 2000-11-24 2001-11-22 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU1846102A Pending AU1846102A (en) 2000-11-24 2001-11-22 Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis

Country Status (9)

Country Link
EP (2) EP1341543A4 (en)
JP (3) JP4162486B2 (en)
KR (1) KR100865142B1 (en)
CN (1) CN100577174C (en)
AU (2) AU1846102A (en)
CA (1) CA2429817C (en)
IL (1) IL156015A0 (en)
MX (1) MXPA03004517A (en)
WO (1) WO2002041827A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP4162486B2 (en) * 2000-11-24 2008-10-08 ヴァスキュラー バイオジェニックス リミテッド Methods using defined oxidized phospholipids and compositions containing such oxidized phospholipids for preventing and treating atherosclerosis
AU2003243806A1 (en) * 2002-07-15 2004-02-02 Bernd Binder Lipid oxidation products for inhibiting inflammation
AU2007200090B2 (en) * 2004-07-09 2011-09-22 Vascular Biogenics Ltd. Improved Process for the Preparation of Oxidized Phospholipids
NZ553147A (en) * 2004-07-09 2010-07-30 Vascular Biogenics Ltd Improved process for the preparation of oxidized phospholipids
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
KR101159406B1 (en) * 2008-03-17 2012-06-28 이화여자대학교 산학협력단 A Composition for the coating of a stent for the prevention of a restenosis and the stent manufactured using the same
ME01898B (en) 2008-08-12 2014-12-20 Zinfandel Pharmaceuticals Inc Method of identifying alzheimer's disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP2348864A4 (en) 2008-10-08 2013-07-31 Vascular Biogenics Ltd Oxidized thiophospholipid compounds and uses thereof
WO2010052718A1 (en) 2008-11-06 2010-05-14 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
CA2786060A1 (en) * 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Treatment with vb-201
JP2014505055A (en) 2011-01-10 2014-02-27 ジンファンデル ファーマシューティカルズ インコーポレイテッド Methods and formulations for treating Alzheimer's disease
ES2768266T3 (en) 2011-09-01 2020-06-22 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids
EP2858517B1 (en) * 2012-06-11 2019-10-30 The Cleveland Clinic Foundation Treatment and prevention of cardiovascular disease and thrombosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CA2968790A1 (en) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
DE3307925A1 (en) * 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln NEW 0-ACYL-ALKANDIOL PHOSPHOLIPIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (en) * 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd Novel glycerin derivative, its preparation and drug containing it
JPS60104066A (en) * 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd Glycerin derivative, its preparation, and drug containing it
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
DE3663522D1 (en) 1985-11-29 1989-06-29 Takeda Chemical Industries Ltd Phospholipid derivatives, their production and use
JPH01502584A (en) * 1986-03-24 1989-09-07 ザ ユニバーシティー オブ シドニー antigenic substance
JPS6354386A (en) * 1986-08-26 1988-03-08 Takeda Chem Ind Ltd Phospholipid and use thereof
JPH01258691A (en) * 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd Phospholipid derivative and production thereof
ES2019552A6 (en) * 1990-04-11 1991-06-16 Menarini Lab Process for the preparation of glycerophospholipids
US5561052A (en) 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
FR2714382B1 (en) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipids vector of active molecule, their preparation and their use in cosmetic or dermatological compositions.
EP0742822B1 (en) 1994-01-31 2004-09-22 The Institute of Cancer Research: Royal Cancer Hospital Folding proteins
AU1751795A (en) * 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
JP3364313B2 (en) * 1994-03-22 2003-01-08 株式会社トクヤマ Porphyrin / indium complex and anion-sensitive membrane
US6156500A (en) 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6034102A (en) 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US5945308A (en) 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US6701176B1 (en) 1998-11-04 2004-03-02 Johns Hopkins University School Of Medicine Magnetic-resonance-guided imaging, electrophysiology, and ablation
JP4162486B2 (en) * 2000-11-24 2008-10-08 ヴァスキュラー バイオジェニックス リミテッド Methods using defined oxidized phospholipids and compositions containing such oxidized phospholipids for preventing and treating atherosclerosis

Similar Documents

Publication Publication Date Title
AU2002218461A1 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
IL156015A0 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002364364A1 (en) Method of treating apoptosis and compositions thereof
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
IL156770A0 (en) Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
AU2002211379A1 (en) Compositions and methods for treatment of cystic fibrosis
AU3591301A (en) Ester derivatives of dimethylpropionic acid and pharmacetuical compositions containing them
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
AU2001286983A1 (en) Method of treatment
AU2001259817A1 (en) Methods of and compounds for inhibiting calpains
AU4057300A (en) Compositions and methods for modifying toxic effects of proteinacious compounds
AU4610701A (en) Chlorine dioxide chelate compositions and method of use
AU3065999A (en) Compositions and methods for treatment of asthma
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2001251352A1 (en) Brake cleaner compositions and method of using same
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU2001262177A1 (en) Method of treatment
IL176976A0 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU1459500A (en) Dihydropyridine compounds and methods of use
AU2221400A (en) Compositions containing and methods of using n-acyl-1h-aminoindenes